---
layout: default
title: Durvalumab
description: "Durvalumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 65
evidence_level: L3
indication_count: 10
---

# Durvalumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Durvalumabï¼šå¾éå°ç´°èƒè‚ºç™Œåˆ°æ³Œå°¿é“ä¸Šçš®ç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Durvalumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Durvalumab åŸæœ¬ç”¨æ–¼æ²»ç™‚éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€è†½é“ç™Œã€è‚ç´°èƒç™ŒåŠå­å®®å…§è†œç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ³Œå°¿é“ä¸Šçš®ç™Œ (urothelial carcinoma)** ç›¸é—œè…«ç˜¤æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **å¤šå€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€è†½é“ç™Œã€è‚ç´°èƒç™Œã€å­å®®å…§è†œç™Œã€è†€èƒ±ç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | prostatic urethra urothelial carcinomaã€kidney pelvis sarcomatoid transitional cell carcinomaã€infiltrating bladder urothelial carcinoma sarcomatoid variantã€renal pelvis papillary urothelial carcinomaã€transitional cell carcinomaã€uterine ligament adenocarcinomaã€endocervical carcinomaã€adenoid cystic carcinoma of the cervix uteriã€uterine ligament serous adenocarcinomaã€signet ring cell variant cervical mucinous adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.98% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 13 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. prostatic urethra urothelial carcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.98%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Durvalumab æ˜¯ä¸€ç¨® PD-L1 æŠ‘åˆ¶åŠ‘ï¼Œé€éé˜»æ–· PD-L1 èˆ‡ PD-1/CD80 çš„çµåˆï¼Œ
æ¢å¾© T ç´°èƒå°è…«ç˜¤ç´°èƒçš„å…ç–«ç›£è¦–åŠŸèƒ½ã€‚æ³Œå°¿é“ä¸Šçš®ç™Œé€šå¸¸è¡¨ç¾è¼ƒé«˜çš„ PD-L1 è¡¨ç¾ï¼Œ
ä¸”å·²æœ‰å…¶ä»– PD-1/PD-L1 æŠ‘åˆ¶åŠ‘åœ¨æ³Œå°¿é“ä¸Šçš®ç™Œç²å¾—æ ¸å‡†ã€‚
Durvalumab å·²æ ¸å‡†ç”¨æ–¼è‚Œè‚‰ä¾µçŠ¯å‹è†€èƒ±ç™Œçš„å‰å°æ€§æ²»ç™‚ï¼Œ
å…¶ç™‚æ•ˆå¯èƒ½å»¶ä¼¸è‡³å…¶ä»–éƒ¨ä½çš„æ³Œå°¿é“ä¸Šçš®ç™Œã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT02812420](https://clinicaltrials.gov/study/NCT02812420) | Phase 1 | ACTIVE_NOT_RECRUITING | 54 | è©•ä¼° durvalumab+tremelimumab åœ¨ç„¡æ³•æ¥å— cisplatin çš„é«˜é¢¨éšªæ³Œå°¿é“ä¸Šçš®ç™Œè¡“å‰æ²»ç™‚ |
| [NCT03912818](https://clinicaltrials.gov/study/NCT03912818) | Phase 2 | TERMINATED | 7 | è©•ä¼° durvalumab è¯åˆæ–°è¼”åŠ©åŒ–ç™‚åœ¨è®Šç•°çµ„ç¹”å‹è†€èƒ±ç™Œçš„ç™‚æ•ˆ |
| [NCT03452332](https://clinicaltrials.gov/study/NCT03452332) | Phase 1 | COMPLETED | 20 | ä½åˆ†æ¬¡æ”¾ç™‚è¯åˆ durvalumab å’Œ tremelimumab æ²»ç™‚å¾©ç™¼/è½‰ç§»æ€§å©¦ç§‘ç™Œç—‡ |
| [NCT04065269](https://clinicaltrials.gov/study/NCT04065269) | Phase 2 | RECRUITING | 174 | ATARI è©¦é©—ï¼šATR æŠ‘åˆ¶åŠ‘è¯åˆ olaparib/durvalumab æ²»ç™‚ ARID1A ç¼ºå¤±å©¦ç§‘ç™Œç—‡ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [37467967](https://pubmed.ncbi.nlm.nih.gov/37467967/) | 2023 | Review | Biomed J | å­å®®é ¸å°ç´°èƒç¥ç¶“å…§åˆ†æ³Œç™Œçš„åˆ†å­åŸºç¤å’Œæ²»ç™‚é€²å±•ï¼ŒåŒ…æ‹¬ durvalumab çš„æ‡‰ç”¨ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. kidney pelvis sarcomatoid transitional cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. infiltrating bladder urothelial carcinoma sarcomatoid variant</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. renal pelvis papillary urothelial carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. uterine ligament adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. endocervical carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. adenoid cystic carcinoma of the cervix uteri</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. uterine ligament serous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. signet ring cell variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. intestinal variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001088è™Ÿ | æŠ‘ç™Œå¯§æ³¨å°„åŠ‘ | æ³¨å°„åŠ‘ | éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€è†½é“ç™Œã€è‚ç´°èƒç™Œã€å­å®®å…§è†œç™Œã€è†€èƒ±ç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å…ç–«æ²»ç™‚ (PD-L1 æŠ‘åˆ¶åŠ‘) |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä½åº¦ |
| è‡´åæ€§åˆ†ç´š | ä½åº¦ |
| ç›£æ¸¬é …ç›® | ç”²ç‹€è…ºåŠŸèƒ½ã€è‚è…åŠŸèƒ½ã€å…ç–«ç›¸é—œä¸è‰¯åæ‡‰ |
| è™•ç½®é˜²è­· | æ¨™æº–ç”Ÿç‰©è£½åŠ‘è™•ç½®è¦ç¯„ |

## å®‰å…¨æ€§è€ƒé‡

- **å…ç–«ç›¸é—œä¸è‰¯åæ‡‰**ï¼šè‚ºç‚ã€è‚ç‚ã€çµè…¸ç‚ã€å…§åˆ†æ³Œç—…è®Šã€çš®ç–¹
- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - èˆ‡çš®è³ªé¡å›ºé†‡ï¼ˆHydrocortisoneã€Dexamethasoneã€Prednisone ç­‰ï¼‰æœ‰ä¸­åº¦äº¤äº’ä½œç”¨
  - èˆ‡ Adalimumab æœ‰é‡å¤§äº¤äº’ä½œç”¨
- **ç‰¹æ®Šæ—ç¾¤**ï¼šè‡ªé«”å…ç–«ç–¾ç—…æ‚£è€…éœ€è¬¹æ…ä½¿ç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Adrenal Insufficiency** ğŸŸ¡ Moderate
- Durvalumab can cause immune-mediated adrenal insufficiency.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intens...

**Colitis** ğŸŸ¡ Moderate
- Immune-mediated colitis has been reported with the use of durvalumab.  Monitor patients for signs and symptoms of diarrhea or colitis.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by c...

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- Durvalumab can cause type 1 diabetes mellitus.  Monitor for hyperglycemia or other signs and symptoms of diabetes.  Withhold treatment in cases of severe hyperglycemia until metabolic control is achieved.  Permanently discontinue durvalumab for life-...

**Infections** ğŸŸ¡ Moderate
- Durvalumab may alter the normal immune response and increase susceptibility to infections.  Monitor patients for signs and symptoms of infection and withhold durvalumab treatment for Grade 3 or higher infections, particularly in patients with urinary...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Durvalumab can cause immune-mediated hepatitis.  Caution is recommended when using durvalumab in patients with moderate or severe hepatic impairment as this agent has not been studied in these patients.  Monitor patients for signs and symptoms of hep...

*å¦æœ‰ 3 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Durvalumab å·²æ ¸å‡†ç”¨æ–¼è†€èƒ±ç™Œï¼Œä¸” PD-L1 æŠ‘åˆ¶åŠ‘åœ¨æ³Œå°¿é“ä¸Šçš®ç™Œçš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ã€‚
é æ¸¬é©æ‡‰ç—‡èˆ‡åŸé©æ‡‰ç—‡å…·æœ‰ç›¸åŒçµ„ç¹”å­¸ç‰¹å¾µå’Œå…ç–«å­¸æ©Ÿè½‰ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°ä¸åŒéƒ¨ä½æ³Œå°¿é“ä¸Šçš®ç™Œçš„ç™‚æ•ˆè©•ä¼°
- PD-L1 è¡¨ç¾æ°´å¹³èˆ‡ç™‚æ•ˆçš„ç›¸é—œæ€§ç ”ç©¶
- èˆ‡å…¶ä»–å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘çš„é ­å°é ­æ¯”è¼ƒè©¦é©—


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Vitamin E]({{ "/drugs/vitamin_e/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Vinorelbine]({{ "/drugs/vinorelbine/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Durvalumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/durvalumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_durvalumab,
  title = {Durvalumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/durvalumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
